Clinical trial
Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating…
NCT00416312 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other · Completed
Key facts
| NCT number | NCT00416312 |
|---|---|
| Title | Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma |
| Official title | Dose-Response in Radioimmunotherapy of Lymphoma |
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Study type | Observational |
| Conditions | Lymphoma |
| Intervention type | Device |
| Interventions | Patient-specific dosimetry, conventional dosimetry |
| Enrollment | 9 |
| Start date | Jul 1, 2006 |
| Primary completion | Oct 1, 2009 |
| Completion | Oct 1, 2009 |
| First posted | Dec 28, 2006 |
| Last update posted | Aug 27, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: